These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23465042)

  • 1. Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar lines.
    Hexsel D; Brum C; Siega C; Schilling-Souza J; Dal'Forno T; Heckmann M; Rodrigues TC
    Dermatol Surg; 2013 Jul; 39(7):1088-96. PubMed ID: 23465042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.
    Magid M; Reichenberg JS; Poth PE; Robertson HT; LaViolette AK; Kruger TH; Wollmer MA
    J Clin Psychiatry; 2014 Aug; 75(8):837-44. PubMed ID: 24910934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facing depression with botulinum toxin: a randomized controlled trial.
    Wollmer MA; de Boer C; Kalak N; Beck J; Götz T; Schmidt T; Hodzic M; Bayer U; Kollmann T; Kollewe K; Sönmez D; Duntsch K; Haug MD; Schedlowski M; Hatzinger M; Dressler D; Brand S; Holsboer-Trachsler E; Kruger TH
    J Psychiatr Res; 2012 May; 46(5):574-81. PubMed ID: 22364892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W; Rappl T
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient satisfaction after the treatment of glabellar lines with Botulinum toxin type A (Speywood Unit): a multi-centre European observational study.
    Molina B; Grangier Y; Mole B; Ribe N; Martín Diaz L; Prager W; Paliargues F; Kerrouche N
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1382-8. PubMed ID: 25495499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines.
    Frampton JE; Easthope SE
    Am J Clin Dermatol; 2003; 4(10):709-25. PubMed ID: 14507232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
    Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
    Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles.
    Michaels BM; Csank GA; Ryb GE; Eko FN; Rubin A
    Aesthet Surg J; 2012 Jan; 32(1):96-102. PubMed ID: 22231417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of depression with botulinum toxin A: a case series.
    Finzi E; Wasserman E
    Dermatol Surg; 2006 May; 32(5):645-9; discussion 649-50. PubMed ID: 16706759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
    de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
    Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of incobotulinumtoxinA for treatment of glabellar frown lines: a post hoc pooled analysis of 2 randomized, placebo-controlled, phase 3 trials.
    Jones D; Carruthers J; Narins RS; Coleman WP; Harrington L; Brandt FS; Cohen JL
    Dermatol Surg; 2014 Jul; 40(7):776-85. PubMed ID: 25111351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA treatment of mild glabellar lines in repose.
    Carruthers A; Carruthers J; Lei X; Pogoda JM; Eadie N; Brin MF
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2168-71. PubMed ID: 21134048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA.
    Yu KC; Nettar KD; Bapna S; Boscardin WJ; Maas CS
    Arch Facial Plast Surg; 2012; 14(3):198-204. PubMed ID: 22183059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shrink that frown! Botulinum toxin therapy is lifting the face of psychiatry.
    Wollmer MA; Neumann I; Magid M; Kruger TH
    G Ital Dermatol Venereol; 2018 Aug; 153(4):540-548. PubMed ID: 29667799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
    Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
    J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of aerobic exercise on self-esteem and depressive and anxiety symptoms among breast cancer survivors.
    Segar ML; Katch VL; Roth RS; Garcia AW; Portner TI; Glickman SG; Haslanger S; Wilkins EG
    Oncol Nurs Forum; 1998; 25(1):107-13. PubMed ID: 9460778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.
    Moy R; Maas C; Monheit G; Huber MB;
    Arch Facial Plast Surg; 2009; 11(2):77-83. PubMed ID: 19289677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Botulinum toxin for the treatment of major depressive disorder].
    Hawlik AE; Freudenmann RW; Pinkhardt EH; Schönfeldt-Lecuona CJ; Gahr M
    Fortschr Neurol Psychiatr; 2014 Feb; 82(2):93-9. PubMed ID: 24519192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of botulinum toxin type A in cosmetic facial procedures.
    Jaspers GW; Pijpe J; Jansma J
    Int J Oral Maxillofac Surg; 2011 Feb; 40(2):127-33. PubMed ID: 20965695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study.
    Won CH; Lee HM; Lee WS; Kang H; Kim BJ; Kim WS; Lee JH; Lee DH; Huh CH
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):171-8. PubMed ID: 23301821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.